Xeris Biopharma Holdings, Inc. (XERS) Guidance & Earnings Results
On 2026-08-06 Xeris Biopharma Holdings, Inc. raised guidance: "FY26 total revenue tightened to $385-390M from prior range (not explicitly stated but implied…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
XERSXeris Biopharma Holdings, Inc.Follow XERS — free
—
Price chart with a free account
- Market cap
- 1.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 6 Aug 26 | Raised | FY26 total revenue tightened to $385-390M from prior range (not explicitly stated but implied tightening) · full year |
| 7 May 26 | Raised | FY2026 total revenue guidance tightened to $380M-$390M (raised low end from $375M) · full year |
| 2 Mar 26 | Raised | FY2026 revenue guidance $375M-$390M vs FY2025 actual $292M; >30% growth at midpoint · full year |
| 8 Jan 26 | Raised | Revenue guidance raised to $292M from $285-290M · full year |
| 6 Nov 25 | Raised | FY2025 total revenue guidance raised to $285-$290M from $280-$290M · full year |
| 7 Aug 25 | Raised | FY2025 total revenue raised to $280-290M from $260-275M · full year |
Xeris Biopharma Holdings, Inc. — questions
- What guidance did Xeris Biopharma Holdings, Inc. give?
- On 2026-08-06: "FY26 total revenue tightened to $385-390M from prior range (not explicitly stated but implied tightening)"
- When does Xeris Biopharma Holdings, Inc. report earnings?
- Xeris Biopharma Holdings, Inc.'s next earnings report is expected on 2026-11-05.
Every figure on this page comes from Xeris Biopharma Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.